Goy Underscores Impact of BTK Inhibitors in Relapsed/Refractory MCL
Published: Tuesday, Apr 07, 2020
Andre Goy, MD, MS
BTK inhibitors have expanded the armamentarium of relapsed/refractory mantle cell lymphoma (MCL), said Andre Goy, MD, MS, adding that this class of agents has elicited unprecedented and durable responses in this patient population.
... to read the full story